DUBLIN–(BUSINESS WIRE)–The “Global Liquid Biopsy Market 2018-2035: Distribution by Application, Target Disease Indication, Type of Circulating Biomarker, Type of Sample, End-users, Stage of Development, Type of Product, Type of Technique, Application Area and Key Geographical Regions” report has been added to ResearchAndMarkets.com’s offering.
The global liquid biopsy market is projected to expand significantly, exhibiting a robust compounded annual growth rate (CAGR) of 15.2% through the year 2035. The report underlines key factors propelling market growth, including the increasing demand for early cancer detection and the surging inclination toward non invasive diagnostic methods.
As the world grapples with a mounting burden of cancer cases, medical communities worldwide are intensively exploring early detection techniques that could potentially improve treatment outcomes and patient survival rates. Liquid biopsy is hailed as a transformative approach in this research domain, especially for its targets in non invasive cancer diagnosis, patient monitoring, and precision medicine.
According to the analysis detailed in the research study, liquid biopsy, due to its minimally invasive nature and improved accuracy, is becoming an indispensable tool in oncology, responding to the critical need for early cancer detection strategies. The study provides an in-depth market distribution by application, target disease indication, type of circulating biomarker, type of sample, end-users, stage of development, type of technique, and geographical regions.
Furthermore, the research publication signals an era of collaboration and innovation within the liquid biopsy field, highlighted by increasing partnerships and funding initiatives, that are set to redefine the landscape of cancer diagnostics. These collaborations are not only accelerating the development of state-of-the-art liquid biopsy products but also fostering advancements in their commercialization.
Key Market Insights
North America holds a significant share of the liquid biopsy market, with numerous companies actively investing in research and development. Asia-Pacific regions are identified as high growth areas, owing to recent advancements and adoptions of such tests. The European market is also a strong contributor to the liquid biopsy market space.
An increase in regulatory approvals and reimbursement for liquid biopsy tests, such as the Guardant360 CDx, indicates a growing acceptance and reliance on these methods for cancer management.
Stakeholders have established numerous strategic collaborations aimed at enhancing their diagnostics offerings, reflecting the sector’s dynamic nature and its emphasis on constant technological evolution.
The study unpacks the distribution of the current and forecasted liquid biopsy market opportunity across various applications, such as early cancer detection, patient monitoring, and therapy selection. The market analysis further delves into the roles of different market stakeholders and depicts a detailed competitive landscape, indicating that over 160 manufacturers are innovating in this space, with North America as the innovation hotspot.
The liquid biopsy market research offers invaluable insights for healthcare professionals, cancer researchers, diagnostic companies, and policymakers, providing them a detailed exploration of this groundbreaking technology. It serves as a crucial resource for understanding the pivotal role liquid biopsy plays today and its anticipated impact on the future of cancer diagnostics.
The emergence of liquid biopsy is a testament to the healthcare industry’s ongoing commitment to enhance the precision and patient-friendliness of cancer diagnostics, with this market study standing as an essential read for those committed to the advancement of cancer care.
Regional Analysis and Market Trends
Segment-wise, the report extensively covers the predominance of circulating tumor DNA among other types of circulating biomarkers, which is expected to dominate the market share. Moreover, highlighting the current state and regional analysis of the liquid biopsy market, the research emphasizes North America and Europe as traditional hubs, while underscoring the rapid rise of the Asia-Pacific region in the liquid biopsy domain.
The report provides a 360-degree view of influential market trends, including the increasing prevalence of cancer, regulatory support, technological advancements, and escalating global healthcare expenditures on cancer care, making the publication an indispensable resource for stakeholders looking to navigate the complexities of the liquid biopsy market.
Key Attributes:
Report Attribute
Details
No. of Pages
331
Forecast Period
2023 – 2035
Estimated Market Value (USD) in 2023
$5.4 Billion
Forecasted Market Value (USD) by 2035
$29.5 Billion
Compound Annual Growth Rate
15.2%
Regions Covered
Global
Key Topics Covered:
Non-Invasive Cancer Screening And Diagnosis
Liquid Biopsy: Market Landscape
Company Profiles
Partnerships And Collaborations
Funding And Investment Analysis
Product Competitiveness Analysis
Big Pharma Initiatives
Key Acquisition Targets
Other Non-Invasive Cancer Diagnostics
Market Impact Analysis: Drivers, Restraints, Opportunities And Challenges
Global Liquid Biopsy Market
Liquid Biopsy Market, By Application
Liquid Biopsy Market, By Target Disease Indication
Liquid Biopsy Market, By Type Of Circulating Biomarker
Liquid Biopsy Market, By Type Of Sample
Liquid Biopsy Market, By Type Of End-User
Liquid Biopsy Market, By Key Geographical Regions
Companies Mentioned
4basebio
4D Lifetec
50K Ventures
8VC
A&G Pharmaceutical
Abbott
AccessHope
AccuraGen
Ackermans & van Haaren
Acobiom
ACT Genomics
Acuamark Diagnostics
Agendia
Agilent Technologies
aiGENE
Alligator Bioscience
Ally Bridge Group
Amadix
Amgen
Anchor Molecular
ANGLE
Annoroad Gene Technology
Anthill Ventures
Apostle
Arboretum Ventures
ARCH Venture Partners
Archangel Investors
ArcherDX
ARNA Genomics
Arquer Diagnostics
Artiman Ventures
ARUP Laboratories
Arvinas
Astellas Pharma
AstraZeneca
Asuragen
Aurum Ventures
AWSensors
BeAble Capital
BGI Genomics
Bio-Rad
BioCaptiva
Biocartis
Biocept
BioChain
Biodesix
BioFluidica
Biological Dynamics
BlackRock
Blue Pool Capital
BNO BIO
Boehringer Ingelheim
Boulder Ventures
BrightEdge
Bristol Myers Squibb
Broadway Angels
BW Ventures
C2i Genomics
Canostix
Caris Life Sciences
Carrum Health
CDBI Partners
Celgene
CellMax Life
Cepheid
CPH Capital
CRF Investment
Curta
Cyclomics
Decheng Capital
Delee
Denlux Capital
DermTech
Detong Capital
Devyser
DiaCarta
DiaDx
Diagnolita
DSC Investment
DT Capital
Dxcover
EarlyDx
EDBI
EDP Biotech
Eisai
Eli Lilly
Elicio Therapeutics
Enterix
Epic Sciences
Exact Sciences
ExBiome
Exosomics
F-star
Faro Capital
Flatiron Health
Fluxion Biosciences
Forestone Capital
Fortune Fountain Capital
Fosun Pharmaceutical
Freenome
Fulgent Genetics
Furong Investment
GeneCast Biotechnology
GENinCode
Genomictree
Genostics
GILUPI
Glycanostics
GRAIL
Guardant Health
Gurnet Point Capital
Hadean Ventures
Hatteras Venture Partners
HDFC
HEDA Ventures
Helio Genomics
HighLight Capital
Horizon
Hummingbird Diagnostics
Hyderabad Angels
ICBC International
Ikonisys
Illumina
Imperial Innovations
Incyte
Inivata
Innovatus Capital Partners
Inova Strategic Investments
INOVIQ
Inventures
Invest4OncoDNA
INVITEK Molecular
IP Group
iSelect Fund
IVDiagnostics
Janus Henderson Investors
Jennison Associates
Johnson & Johnson
Junci Investment
Junson Capital
KEODES
Kexin Capital
Khosla Ventures
Labcorp
LeapFrog Investments
Lexent Bio
Lilly Asia Ventures
Linden Capital Partners
Longwood Fund
Loyal Valley Capital
LU Holding
Lucence
LungLife AI
LYFE Capital
MagBio Genomics
McKesson Ventures
MDxHealth
MedGenome
Merck
MiCareo
Micronoma
Miltenyi Biotec
Minomic
miR Scientific
Mirati Therapeutics
MiRXES
Mitsui
Multimmune
Mumbai Angels
myNEO
Myriad Genetics
Nan Fung Group
Nanostics
NantHealth
Natera
Naveris
NeoGeneStar
Nonacus
Northpond Ventures
Novartis
Novigenix
Novo Holdings
NRG Oncology
nRichDX
Nucleix
NVIGEN
Ochsner Health
OCI Bio Investments
Old College Capital
Omnigen
Oncimmune
OncoDNA
OrbiMed
Pacific Edge
Parampara Fund
PBM Capital
Perceptive Advisors
PeriRx
Personalis
Pfizer
Pillar Biosciences
Positive Bioscience
Predicine
Premier
Promega
Prosperico Venture
Provista Diagnostics
Proxima Ventures
Q2 Solutions
QIAGEN
Quest Diagnostics
Qure
R-Cubed Capital
Rarecells
Resolution Bioscience
RGCC Group
Rock Springs Capital
Rongsheng Investment
RT Ventures
SAGA Diagnostics
Saha Fund
Sambrinvest
Sands Capital
Sangel Capital
Sansure Biotec
Saphetor
Scottish Enterprise
ScreenCell
Sebela Pharmaceuticals
SensID
Sequoia Capital
Servier
SIMFO
Singlera Genomics
Sky Ventures
Sofina
Sofinim
SoftBank Ventures
Soleus Capital
Sozo Ventures
SPD Scientific
StageZero Life Sciences
StartX
Sutter Hill Ventures
Swelife
SYMBIOSIS
Takara Bio
Tecan
Tempus
Tesis Biosciences
Thermo Fisher Scientific
Todos Medical
Virtus Health
VolitionRx
Vortex Biosciences
Windham Venture Partners
Wisemont Capital
WntResearch
WRF Capital
WS Investment
X-ZELL
XboXLab
Yemaachi Biotech
Yi Fang Group
Zehou Capital
ZERO Prostate Cancer
Zinexts Life Science
Zodius
Zogen Genética Molecular
For more information about this report visit https://www.researchandmarkets.com/r/4y9w53
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
